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Antiretroviral chemoprophylaxis: PROUD and pragmatism
About 20 years ago, very shortly after antiretroviral drugs 
were ﬁ rst shown to inhibit HIV replication and improve 
clinical outcomes, studies of animals showed that pre-
exposure and post-exposure antiretroviral treatment 
could protect against retroviral challenges.1 The ﬁ rst use 
of antiviral drugs for chemoprophylaxis in human beings 
was that of zidovudine in HIV-infected pregnant women 
to prevent transmission to their children.2 Subsequently, 
seven eﬃ  cacy trials of antiretroviral primary prevention 
have shown that tenofovir-based regimens can prevent 
HIV acquisition in African male and female heterose xuals, 
men and transgender women who have sex with men 
in Asia, Africa, Europe, and the Americas, and men and 
women in Thailand who inject drugs.3–9 Protection 
was directly correlated with adherence to treatment. 
Individuals who were highly adherent achieved levels 
of protection that exceeded those associated with 
consistent condom use.10
Despite early studies showing the eﬃ  cacy of 
antiretroviral pre-exposure prophylaxis (PrEP), wide-
spread uptake has not been immediate. Because the 
safety threshold for the use of drug treatments by 
otherwise healthy people must be high, concerns were 
raised about the potential for tenofovir–emtricitabine to 
cause symptoms, to be nephrotoxic, or to deplete bone 
mineral density, although initial studies3–9 of thousands 
of participants showed that, with routine monitoring, 
adverse events were few, and were readily manageable. 
Some commentators suggested that irregular use of 
antiretroviral drugs could lead to selection for drug-
resistant strains, but few PrEP-related resistant infections 
have been recorded, primarily because most individuals 
who became infected were non-adherent, limiting 
selection pressure.11 Because tenofovir–emtricitabine is 
expensive in many countries (up to US$15 000 per year), 
some questioned whether PrEP could be cost eﬀ ective. 
However, in high-incidence settings, access to PrEP by 
people at greatest risk for infection could save money, 
since PrEP use can be limited to a period of risk, whereas, 
if HIV infection occurs, treatment with more expensive 
triple antiretroviral combination treatment is lifelong.12
The most contentious concerns about PrEP involve risk 
compensation: the fear that increased access to PrEP would 
lead people to abandon condom use. This hypothesis 
reﬂ ects an odd mix of naivety and moralism. If condoms 
were being consistently used, the rates of new HIV 
infections would not remain at 2 million new infections 
per year.13 Rates of new HIV infections remain alarmingly 
high in several key populations (ie, young women in Africa, 
men who have sex with men and transgender women in 
most countries, sex workers, and people who inject drugs 
in countries that were part of the former Soviet Union,13 
where access to eﬀ ective prevention methods, such as 
clean syringes and opiate substitution treatment, have 
been supplanted by punitive laws and mass incarceration). 
The existence of coercive policies aﬀ ecting vulnerable 
populations has led some advocates to question whether 
PrEP implementation could increase stigma and coercion 
by medicalising HIV risk, enabling authorities to avoid 
dealing with social drivers of HIV spread.
Others have questioned whether PrEP could be readily 
implemented outside the controlled environment 
of a clinical trial and remain suﬃ  ciently eﬀ ective to 
warrant wider use. According to Sheena McCormack and 
colleagues’ PROUD study8 published in The Lancet, the 
answer is a resounding yes. The investigators enrolled 
544 men who have sex with men who were seeking 
services at English sexual health clinics, and randomly 
assigned them to immediate PrEP (n=275) or deferred 
PrEP (n=269), to begin after 1 year. The deferred group 
had to be ended early, because of the 86% eﬃ  cacy 
(90% CI 64–96) in the immediate group. There was a 
worrying 9% yearly HIV incidence rate in the deferred 
PrEP group, who received counselling, condoms, and 
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post-exposure prophylaxis on demand, compared with a 
rate of 1·2% in the immediate PrEP group. The number 
needed to treat to prevent one new HIV infection per 
year was 13. This number compares favourably with 
most public heath preventive interventions (eg, statins 
to prevent cardiovascular or cerebrovascular events); and 
in 2017, this ﬁ xed drug combination’s patent will expire, 
lowering costs worldwide. 
So, where do we go from here? The results from PROUD 
suggest that pragmatic deployment of PrEP must be 
part of any relevant primary HIV prevention strategy. 
Identifying and oﬀ ering treatment to all people with 
HIV must also be a priority for their personal health, 
and to decrease HIV transmission.14 But, given that 
more than 20 million people with HIV are not yet taking 
antiretroviral drugs,13 and many are unaware that they 
are infected, universal treatment will take time and might 
be insuﬃ  cient to control HIV spread in high incidence 
networks. In such settings, ﬁ rst generation oral PrEP can 
be deployed to arrest further spread. Further reﬁ nements 
of PrEP could involve intermittent or coitally dependent 
dosing, intravaginal rings, injectable chemoprophylaxis, 
or immunoprophylaxis.15 However, the PROUD results 
show that PrEP should be part of the range of services 
oﬀ ered by any clinical programme that focuses on sexual 
health. The time for cautionary speculation is over: HIV 
prevention services should be expanded worldwide by 
oﬀ ering PrEP routinely to those who could beneﬁ t.
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Whatever the details of the agreement that emerges 
from the UN Framework Convention on Climate Change 
conference in Paris, France, in December, 2015, a key 
challenge will be how to implement policies to achieve 
the negotiated reductions in greenhouse gas emissions. 
Carbon pricing is, according to economic theory, the 
most eﬃ  cient way to reduce carbon emissions.1 Such 
pricing can reﬂ ect at least part of the damage resulting 
from fossil fuel combustion or other sources of 
greenhouse gas emissions, and thus their true costs to 
society. Moreover, global energy subsidies are suggested 
to have amounted to about US$5·3 trillion in 2015,2 
Health beneﬁ ts of a carbon tax
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